48 completed, 12 terminated, 4 withdrawn, 1 active not recruiting. 37 Phase 2, 22 Phase 1, 9 Not applicable, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 24, Terminated 9, Withdrawn 4 |
| Phase 1 | 22 | Completed 17, Terminated 5 |
| Not applicable | 9 | Completed 8, Terminated 1 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow Stage III Multiple Myeloma: new trials by email Literature Review of Stage III Multiple Myeloma trials Research Report on Stage III Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma bortezomib, cyclophosphamide, dexamethasone - Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2015-04-01 | 2015-04-24 | |
| Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Bendamustine hydrochloride, Bortezomib, Dexamethasone - Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 24 | 2014-08-25 | 2025-04-30 |
| Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 | Terminated | Case Comprehensive Cancer Center | 8 | 2013-10-07 | 2017-02-17 |
| Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant carfilzomib, dexamethasone, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Withdrawn | Mayo Clinic | 2013-08-01 | 2016-12-19 | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma dexamethasone, cisplatin, doxorubicin - Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone | Phase 2 | Completed | Margarida Magalhaes-Silverman | 41 | 2013-04-04 | 2022-05-11 |
| Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma dexamethasone, carfilzomib, lenalidomide - Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Completed | University of Chicago | 76 | 2013-01-01 | 2026-04-21 |
| Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy romiplostim - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Terminated | NYU Langone Health | 5 | 2013-01-01 | 2018-10-15 |
| Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant bortezomib, cyclophosphamide, lenalidomide - Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Completed | Mayo Clinic | 3 | 2012-12-07 | 2018-09-17 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients cryotherapy, questionnaire administration, pharmacological study - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 148 | 2012-04-01 | 2017-06-27 |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant pharmacological study, tacrolimus, sirolimus - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 1 | 2012-02-01 | 2017-04-05 |
| Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma dalteparin, lenalidomide, dexamethasone - Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Terminated | University of Southern California | 13 | 2012-01-09 | 2017-11-29 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma bortezomib, filgrastim, autologous hematopoietic stem cell transplantation - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 23 | 2011-07-01 | 2021-05-10 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer palifermin, flow cytometry, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Martin, Paul | 6 | 2010-09-01 | 2014-04-02 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies plerixafor, filgrastim, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Terminated | Fred Hutchinson Cancer Center | 1 | 2010-06-01 | 2017-06-28 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
Showing 20 of 65. Sign in to see all of them.
Multiple Myeloma (65) · Leukemia, Lymphocytic, Chronic, B-Cell (26) · Lymphoma, Large B-Cell, Diffuse (25) · Burkitt Lymphoma (24) · Lymphoma, Follicular (24) · Lymphoma, Mantle-Cell (24) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Lymphoma, Non-Hodgkin (23) · Lymphoma, B-Cell, Marginal Zone (22) · Lymphoma, Large-Cell, Immunoblastic (22) · Lymphoma, T-Cell, Cutaneous (20) · Hodgkin Disease (19) · Mycosis Fungoides (19) · Sezary Syndrome (19) · Congenital Abnormalities (15)
Blood Protein Disorders (65) · Cardiovascular Diseases (65) · Hematologic Diseases (65) · Hemic and Lymphatic Diseases (65) · Hemorrhagic Disorders (65) · Hemostatic Disorders (65) · Immune System Diseases (65) · Immunoproliferative Disorders (65) · Lymphoproliferative Disorders (65) · Neoplasms by Histologic Type (65) · Paraproteinemias (65) · Vascular Diseases (65) · Neoplasms (63) · Neoplasms, Plasma Cell (62) · Chronic Disease (26)
Bortezomib (15) · Dexamethasone (14) · Calcium Dobesilate (12) · Peripheral Blood Stem Cell Transplantation (11) · Cyclophosphamide (10) · Lenalidomide (9) · Whole-Body Irradiation (9) · Melphalan (8) · Mycophenolic Acid (8) · fludarabine phosphate (8) · Cyclosporine (7) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Sirolimus (4) · Tacrolimus (4)
National Cancer Institute (NCI) (21) · Fred Hutchinson Cancer Center (16) · City of Hope Medical Center (5) · Mayo Clinic (4) · Barbara Ann Karmanos Cancer Institute (2) · Case Comprehensive Cancer Center (2) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2) · Wake Forest University Health Sciences (2) · Amir Mortazavi (1) · Margarida Magalhaes-Silverman (1) · Martin, Paul (1) · NYU Langone Health (1) · Ohio State University Comprehensive Cancer Center (1) · Oncotherapeutics (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (64) · Italy (5) · Germany (2) · Canada (1) · South Africa (1)
David Maloney (6) · Leona Holmberg (3) · Paul Martin (3) · Shaji Kumar (3) · William Bensinger (3) · Angela Dispenzieri (2) · Joseph R. Mikhael, M.D. (2) · Ryotaro Nakamura (2) · Alan Lichtenstein (1) · Alexander Stewart (1) · Amir Mortazavi, MD (1) · Amitabha Mazumder (1) · Amrita Krishnan (1) · Andrzej Jakubowiak (1) · Ann Mohrbacher, MD (1)
PMID 32499241, PMID 18698002, PMID 18974373, PMID 23887852, PMID 24241210, PMID 26764356, PMID 26853648, PMID 26943915, PMID 28150872, PMID 28270022, PMID 28817727, PMID 30562587, PMID 32628342, PMID 32735641, PMID 33420905, PMID 33492438, PMID 35549810, PMID 36282798
P30CA015704 (7), P01CA078902 (3), U10CA021115 (3), N01CM62204 (2), N01CM62205 (2), P30CA016058 (2), P30CA043703 (2), U01CA062491 (2), U01CA062502 (2), U01CA069912 (2), U01CA076576 (2), N01CM00070 (1), N01CM17104 (1), N01CM62203 (1), N01CM62207 (1)